Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Scottish reforms to decriminalise personal drug use knocked down within an hour

Scottish drugs minister Elena Whitham said ‘criminalisation increases the harms people experience. Criminalisation kills’.

The Independent UK

Drugs minister ‘terrified’ of potential impact of failure to reform policy

Downing Street re-committed to its ‘tough’ stance on drugs as the Scottish Government called for decriminalisation of personal use.

The Independent UK

Ministers cannot be the last to know when inward investors like Zimmer Biomet pull out of Wales

A more constructive approach to managing relationships with major employers is important in the future especially if they are in receipt of public funding.

Birmingham Post

From analysis to the latest developments in health,
read the most diverse news in one place.

RSS’s pharma body writes to Health Ministry criticising risk-based inspections, backtracks later

In a strongly worded letter to the Union Health Ministry, the Rashtriya Swayamsewak Sangh- (RSS) backed Laghu Udyog Bharati, which represents over 300 micro and small industries across India, has said the Union government’s risk-based inspections (RBI) on pharma companies were draconian and have been a huge discouragement to the…

The Hindu

Biogen Skids As Analysts Debate Uptake For Newly Approved Alzheimer's Drug

Biogen stock skidded Friday after the Food and Drug Administration fully approved its Alzheimer's treatment, Leqembi.

Investors Business Daily

AbbVie (ABBV) vs. Pfizer (PFE) - Which Pharma Stock Comes out on Top?

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

StockNews.com

Moderna signs deal to make mRNA vaccines for Chinese market

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire

Chinook wasn't looking to sell when Novartis approached. But the deal might be the best bet for patients — and KDNY stockholders.

Investors Business Daily

Regulation for all medical devices from October 1, says DCGI

India is on course to introduce regulations governing all the medical devices in the country on October 1, Drugs Controller General of India Rajeev Singh Raghuvanshi said at iPhex 2023

The Hindu

Which Pharma Stock Is the Better July Pick: Johnson & Johnson (JNJ) or Curaleaf Holdings (CURLF)?

On the backs of increasing medical requirements amid the soaring incidence of chronic diseases, the pharmaceutical industry’s outlook radiates promise. Given this backdrop, let us compare pharma stocks Johnson & Johnson (JNJ) and Curaleaf Holdings (CURLF) to discover which one of these could be worth buying in July. Read on….

StockNews.com

Medicare To Negotiate Drug Prices, Lower Costs

CMS releases guidance on using authority to expand benefits, reduce drug costs, and strengthen Medicare program.

Zenger

Pharmacies receive $377m medication sweetener

Pharmacies will be paid thousands more to dispense medicines from July 1 as part of a government funding boost.

AAP

Will lower-cost Humira pharmaceutical options soon be available to patients?

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings?

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Is Catalyst Pharmaceuticals (CPRX) a Quality Investment?

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) delivered a robust performance in the first quarter of 2023. However, it fell short of analysts’ estimates. Let’s dig into some of its financial metrics to determine whether CPRX is worth buying ahead of the upcoming earnings season.

Wales Online

Deep concern as Zimmer Biomet closure in Bridgend puts 540 jobs at risk

The announcement has left a community in shock

Birmingham Post

Andor Technologies sets sights on £20M of exports with new scientific microscope

The company said the new product represents disruptive technology and will see it break into new markets

The Independent UK

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Reata Surges 12% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug

Reata CEO Warren Huff says Friedreich's ataxia is "the worst disease." Now, RETA stock investors are watching the long-awaited drug launch.

Birmingham Post

Hundreds of jobs at threat at South Wales hip replacement factory

Zimmer Biomet has confirmed plans to close its factory in Bridgend

Wales Online

540 jobs at risk as Bridgend Zimmer Biomet plant set to close

Zimmer Biomet in Bridgend has entered into consultation with its staff

The Hindu

India takes first step to remove animals from drug-testing process

Every drug in the market goes through a long journey of tests, each designed to check whether it can treat the disease for which it was created and whether it has any unintended harmful effects. For a long time, the first step of this process was to test the candidate…

StockNews.com

2 Biotech Stocks to Buy, 1 to Sell Now

The biotech industry is well-positioned for long-term growth thanks to increasing demand for quality healthcare, a rapidly aging population, and rising chronic diseases. Therefore, buying fundamentally strong biotech stocks Entrada Therapeutics (TRDA) and ProQR Therapeutics N.V. (PRQR) could be wise. On the other hand, one should consider selling 4D Molecular…

StockNews.com

3 Medical Stocks to Buy for Great Value

Owing to the rising prevalence of chronic medical conditions and awareness among the patient population, the medical industry is poised for remarkable growth. Therefore, it could be wise to scoop up the shares of quality medical stocks Medtronic plc (MDT), FONAR Corporation (FONR), and Electromed, Inc. (ELMD), which carry significant…

StockNews.com

3 Biotech Stocks With Some Major Value in Them

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

1 … 37 38 39 40

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Scottish Government

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.